fbpx
Register Log-in Investor Type

Search

Filters
Types

Sign up for our free
equity research notes

Register
129 Results for ‘international biotechnology’
Embed
International Biotechnology Trust – Healthy returns
201111 IBT

International Biotechnology Trust (IBT) has delivered strong returns over the past 12 months, with the NAV up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The […]

International Biotechnology Trust – Healthy returns
201111 IBT

International Biotechnology Trust (IBT) has delivered strong returns over the past year; its net asset value (NAV) is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and […]

International Biotechnology Trust – Healthy returns
201111 IBT

International Biotechnology Trust (IBT) has delivered strong returns over the past year, the NAV is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The sector has […]

Its been a strong year for International Biotechnology Trust
International Biotechnology benefits from narrowing discount

International Biotechnology Trust’s (IBT) has reported full-year results, to 31 August 2020. IBT’s NAV per share and share price returned 22.4% and 18.7%, whilst the NASDAQ Biotechnology index (NBI) returned 20.6% (to 31 August 2020) and the FTSE All-Share index returned -12.6% (to 28 August 2020). The table below summarises IBT’s cumulative total return performance over […]

International Biotechnology Trust says sector’s long-term fundamentals remain undiminished
International biotechnology - Outperformance and income 4

International Biotechnology Trust’s (IBT) has reported interim results, to 29 February 2020. The pandemic’s sustained impact on financials markets began in March, so the impact on IBT’s portfolio over this results period, was negligible. Over the interim period, the company’s NAV per share returned 3.6%. By comparison, the NASDAQ biotechnology index (NBI) returned 6.0% and […]

International Biotechnology Trust – Trust in biotech

The biotechnology sector is proving to be relatively resilient in this COVID-19 related market sell-off. International Biotechnology Trust (IBT) adopts a conservative approach to investing in what can be a quite volatile, if rewarding, sector. It has fared better than competing funds in this environment. Some delay to drug development, testing programmes and product launches […]

International Biotechnology Trust – Trust in biotech

 Trust in biotech The biotechnology sector is proving to be relatively resilient in this COVID-19 related market sell-off. International Biotechnology Trust (IBT) adopts a conservative approach to investing in what can be a quite volatile, if rewarding, sector and has fared better than its peers in this environment. Some delay to drug development and testing […]

International Biotechnology AGM 2019

International Biotechnology AGM 2019

Unquoteds outperform for International Biotechnology Trust
IBT adds to Celgene, reduces Neurocrine in July rejig

Unquoteds outperform for International Biotechnology Trust – International Biotechnology Trust (IBT) has reported annual results to 31 August 2019. The majority of IBT’s portfolio holdings are based in the US. Headline results: Share price (2.1%) NAV (6.8%) NASDAQ Biotechnology Index (NBI) (9.8%) FTSE All-Share Index: +0.4% Quoted portfolio outperformed benchmark over challenging period IBT’s quoted […]

International Biotechnology Trust – Healthy yield attracts investors

 Healthy yield attracts investors The managers of International Biotechnology Trust (IBT) have focused its portfolio in oncology (cancer), diseases of the central nervous system and rare diseases – areas where pricing pressure on drugs and other therapies is less of an issue. This should cushion IBT as we approach election year in the US and […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…